Article Abstract

Apatinib for EGFR-TKI and chemotherapy refractory in an advanced lung cancer patient: a case report

Authors: Ying Chen, Junping Gong, Huiming Zhou, Xiujuan Qu, Yuee Teng, Yunpeng Liu, Bo Jin


In China, primary lung cancer is one of the most common malignant tumors. The data of China Cancer Center in 2015 showed that the prevalence of lung cancer was 130.2 (1/10 million) from 2006 to 2011 in China. And lung cancer has risen to be the fourth leading cause of death (1). Most patients have distant metastasis when they get initial diagnosis.